Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
The FDA’s commissioner Scott Gottlieb has pledged to crack down on “unscrupulous actors” attempting to treat patients with potentially dangerous or unproven stem cell therapies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
